The mTOR Inhibitor Temsirolimus Added to Rituximab Combined With Dexamethasone, Cytarabine, and Cisplatinum (R-DHAP) for the Treatment of Patients With Relapsed or Refractory DLBCL – Results From the Phase-II STORM Trial

The mTOR Inhibitor Temsirolimus Added to Rituximab Combined With Dexamethasone, Cytarabine, and Cisplatinum (R-DHAP) for the Treatment of Patients With Relapsed or Refractory DLBCL – Results From the Phase-II STORM Trial

There is a high need for novel treatment options in relapsed and refractory diffuse large B-cell lymphoma. Single agent mammalian target of rapamycin (mTOR) inhibitor treatment has shown promising efficacy in this entity. Here, we report on the results of the mTOR-inhibitor temsirolimus combined to...

Full description

Bibliographic Details
Main Authors: Mathias Witzens-Harig, Andreas Viardot, Ulrich Keller, Julia Wosniok, Oliver Deuster, Jennifer Klemmer, Anne-Marie Geueke, Julia Meißner, Anthony D. Ho, Johannes Atta, Reinhard Marks, Paul La Rosée, Christian Buske, Martin H. Dreyling, Georg Hess
Format: Article
Language:English
Published: Wolters Kluwer 2021-10-01
Series:HemaSphere
Online Access:http://journals.lww.com/10.1097/HS9.0000000000000636

Internet

http://journals.lww.com/10.1097/HS9.0000000000000636

Similar Items